Acacb knock-out mice [2], [3], [4] and rats treated with Acaca or Acacb anti-sense nucleotide inhibitors [12] suggested a potential therapeutic target for ACACB in insulin resistance, obesity, metabolic syndrome, and type 2 diabetes. This evidence concerns the gene ACACB and obesity due to melanocortin 4 receptor deficiency.